A Phase 3 interventional study of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution (Combo) and Vehicle of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% ophthalmic solution in Allergic Conjunctivitis, sponsored by Bausch & Lomb Incorporated. Completed at 7 sites in United States. Open to participants aged 5 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-10.
Sponsored by Bausch & Lomb Incorporated (part of Bausch Health Companies Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Conjunctivitis, Allergic by Bausch Health Companies Inc. — none open to participants now, none under way, none of them phase 3. Conjunctivitis, Allergic · Bausch Health Companies Inc..
Among the 17 studies in Conjunctivitis, Allergic by Bausch Health Companies Inc., this one is the 3rd largest by enrollment, is the only one that started in 2023, is one of 11 in phase 3, and was the 17th registered.
211 studies on the registry are indexed under Conjunctivitis, Allergic; 19 are open to participants now.
Browse Conjunctivitis, Allergic studies →None of the 17 studies in Conjunctivitis, Allergic by Bausch Health Companies Inc. is open now. The open studies under Conjunctivitis, Allergic, anywhere →
Of the 12 Conjunctivitis, Allergic studies recruiting now, 8 (67%) set no upper age limit and 4 (33%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.
This study: 5 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 12 · Phase 4 1
First in 2006; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 512 is above the median of 87 across 175 interventional studies indexed under Conjunctivitis, Allergic.
Median enrollment 144 across the 17 interventional studies. Of the 16 that completed or were terminated, 14 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Bausch & Lomb Incorporated, one of the names counted as Bausch Health Companies Inc.. Under that name alone:
Bausch & Lomb Incorporated is the lead sponsor of 223 studies on the registry; 5 are open to participants now.
Of its 51 completed or terminated interventional studies of FDA-regulated products, 41 (80%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 17 studies in Conjunctivitis, Allergic by Bausch Health Companies Inc., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To compare the safety and tolerability of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% combination ophthalmic solution versus its vehicle in healthy adult subjects and in pediatric subjects.
The study will consist of 4-5 study visits to compare the safety and tolerability of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% combination ophthalmic solution versus its vehicle in healthy adult subjects and in pediatric subjects with a history or family history of atopic disease (including allergic conjunctivitis).
To characterize the plasma pharmacokinetics (PK) of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% combination ophthalmic solution following a single dose and 22-day twice daily (BID) topical ocular dosing in a subset of healthy adult subjects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
5 days
artificial tear products, eye whiteners (e.g., vasoconstrictors), ocular decongestants, ocular , ocular antihistamines, and any other topical ophthalmic agents;
14 days
any systemic medications which the investigator feels may confound study data or interfere with subject's study participation;
6. have used contact lenses within 24 hours prior to each visit (Visit 1, 2, 3, and 4);
7. have prior (within 7 days of beginning IP) or currently active significant illness that could compromise participation, in the opinion of the investigator;
8. have prior (within 30 days of beginning investigational product) or anticipated concurrent use of an investigational product or device during the study period;
9. have been randomized in study 909 or 910 conducted by Bausch \& Lomb;
10. be an employee or family member of employee at the investigative site;
11. have an ocular or systemic condition or is in a situation that the investigator feels may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's study participation;
12. have planned surgery (ocular or systemic) during the trial period or within 30 days after;
13. have body weight below the 5th percentile for their age (subjects 12 years of age or younger only) (see Appendix 2);
14. be a female who is currently pregnant, is planning a pregnancy, or lactating;
15. have an abnormal blood pressure (defined as ≤ 90 or ≥ 160 (systolic) measured in mmHg or ≤ 60 or ≥ 100 (diastolic) measured in mmHg). For pediatric subjects, abnormal blood pressure is defined as ≥ 140 (systolic) measured in mmHg or ≥ 90 (diastolic) measured in mmHg;
16. have an intraocular pressure (IOP) that is less than 5 mmHg or greater than 22 mmHg or have a normal IOP with a prior diagnosis/history of glaucoma at Visit 1;
17. have symptoms associated with COVID-19 or have been in contact with someone diagnosed with COVID-19 within 14 days of the Screening Visit or Visit 1 (if Screening and Visit 1 are done on the same day);
18. (for selected healthy adult subjects agreeing to undergo PK blood draws) have excessive consumption of caffeine- or xanthine-containing beverages (more than 4 cups or servings per day) within 48 hours prior to dosing at Visit 1 or for the duration of the study (see Appendix 6);
19. (for selected healthy adult subjects agreeing to undergo PK blood draws) have a history of tobacco, nicotine, or nicotine-containing product use within 12 months prior to Visit 1;
20. (for selected healthy adult subjects agreeing to undergo PK blood draws) have a history or current evidence of drug or alcohol abuse within 12 months prior to Visit 1;
21. (for selected healthy adult subjects agreeing to undergo PK blood draws) have blood donation or equivalent blood loss of >450 mL within 60 days prior to Visit 1.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution (Combo)
Drug: Vehicle of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% ophthalmic solution
Drug page: Brimonidine
Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution (Combo)
Vehicle of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% ophthalmic solution
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
TEAE is defined as any untoward medical occurrence or undesirable event(s) that begins or worsens following administration of the study drug, whether or not considered related to the treatment by the Investigator. A TEAE is considered serious if, in the view of the Investigator or Sponsor, it results in any of the following outcomes: death, a life-threatening TEAE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, an important medical event that jeopardized the participant and required medical intervention, or sight-threatening (possibly resulting in persistent or significant loss of vision)
Time frame: Baseline up to Day 42
Drop Comfort Assessment as Assessed by the Participant
Drop comfort assessment (0-10 unit scale in which a score of 0 denotes "very comfortable" and 10 is "very uncomfortable") was performed by the participantsubjects ≥ 10 years of age
Time frame: At dose installation, 30 seconds post dose installation, and 1-minute post dose installation on Day 1, Day 8 and Day 22
Plasma Concentration: Brimonidine
Blood samples will be collected to measure the concentration of brimonidine. Concentration values reported below the limit of quantification (BLQ) before the first quantifiable concentration or after the last quantifiable concentration were set to zero for concentration descriptive statistics.
Time frame: Pre-Instillation and 15 min, 30 min, 1 hr, 2hr and 4hrs post-instillation on Day 1 and on Day 22.
Plasma Concentration: Ketotifen
Blood samples will be collected to measure the concentration of ketotifen. Concentration values reported below the quantification limit (BLQ) before the first quantifiable concentration or after the last quantifiable concentration were set to zero for concentration descriptive statistics.
Time frame: Pre-Instillation and 15 min, 30 min, 1 hr, 2hr and 4hrs post-instillation on Day 1 and on Day 22.
| Milestone | Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution | Vehicle Ophthalmic Solution |
|---|---|---|
| Started | 340 | 172 |
| Completed | 309 | 158 |
| Not completed | 31 | 14 |
| Withdrew: Adverse event | 6 | 2 |
| Withdrew: Lost to follow-up | 14 | 1 |
| Withdrew: Withdrawal by subject | 6 | 6 |
| Withdrew: Protocol violation | 1 | 1 |
| Withdrew: Discontinued | 4 | 4 |
TEAE is defined as any untoward medical occurrence or undesirable event(s) that begins or worsens following administration of the study drug, whether or not considered related to the treatment by the Investigator. A TEAE is considered serious if, in the view of the Investigator or Sponsor, it results in any of the following outcomes: death, a life-threatening TEAE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, an important medical event that jeopardized the participant and required medical intervention, or sight-threatening (possibly resulting in persistent or significant loss of vision)
| Participants | Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution | Vehicle Ophthalmic Solution |
|---|---|---|
| Number of Subjects with at Least One TEAE | 61 | 19 |
| Number of Subjects with at Least One Ocular TEAE | 38 | 10 |
| Number of Subjects with at Least One Non-Ocular TEAE | 28 | 9 |
| Number of Subjects with at Least One Non-Ocular TE-SAE | 0 | 1 |
| Number of Subjects with Treatment-Related TEAEs | 34 | 7 |
| Number of Subjects with TEAEs by Maximum Severity (Mild) | 54 | 16 |
| Number of Subjects with TEAEs by Maximum Severity (Moderate) | 7 | 3 |
| Number of Subjects with TEAEs Leading to Early Treatment Discontinuation | 7 | 3 |
Drop comfort assessment (0-10 unit scale in which a score of 0 denotes "very comfortable" and 10 is "very uncomfortable") was performed by the participantsubjects ≥ 10 years of age
| score on a scale | Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution | Vehicle Ophthalmic Solution |
|---|---|---|
| Visit 1 (Day 1) immediately upon instillation | 0.98 ± 1.599 | 0.56 ± 1.190 |
| Visit 1 (Day 1) 30 seconds post instillation | 0.59 ± 1.250 | 0.38 ± 0.959 |
| Visit 1 (Day 1) 1 minute post instillation | 0.41 ± 1.019 | 0.29 ± 0.866 |
| Visit 2 (Day 8) immediately upon instillation | 1.13 ± 1.665 | 0.43 ± 0.964 |
| Visit 2 (Day 8) 30 seconds post instillation | 0.54 ± 1.172 | 0.28 ± 0.929 |
| Visit 2 (Day 8) 1 minute post instillation | 0.30 ± 0.906 | 0.21 ± 0.758 |
| Visit 3 (Day 22) immediately upon instillation | 0.93 ± 1.512 | 0.50 ± 1.109 |
| Visit 3 (Day 22) 30 seconds post instillation | 0.34 ± 0.904 | 0.25 ± 0.895 |
| Visit 3 (Day 22) 1 minute post instillation | 0.15 ± 0.558 | 0.18 ± 0.706 |
Blood samples will be collected to measure the concentration of brimonidine. Concentration values reported below the limit of quantification (BLQ) before the first quantifiable concentration or after the last quantifiable concentration were set to zero for concentration descriptive statistics.
| ng/ml | Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution | Vehicle Ophthalmic Solution |
|---|---|---|
| Visit 1 (Day 1) Pre-instillation | 0 (0 to 0) | 0 (0 to 0) |
| Visit 1 (Day 1) 15 min post instillation | 0 (0 to 0) | 0 (0 to 0) |
| Visit 1 (Day 1) 30 min post instillation | 0 (0 to 0) | 0 (0 to 00) |
| Visit 1 (Day 1) 1 hr post instillation | 0 (0 to 0) | 0 (0 to 0) |
| Visit 1 (Day 1) 2 hrs post instillation | 0 (0 to 28.1) | 0 (0 to 0) |
| Visit 1 (Day 1) 4 hrs post instillation | 0 (0 to 24.2) | 0 (0 to 0) |
| Visit 3 (Day 22) Pre-instillation | 0 (0 to 0) | 0 (0 to 0) |
| Visit 3 (Day 22) 15 min post instillation | 0 (0 to 0) | 0 (0 to 0) |
| Visit 3 (Day 22) 30 min post instillation | 0 (0 to 0) | 0 (0 to 0) |
| Visit 3 (Day 22) 1 hr post instillation | 0 (0 to 0) | 0 (0 to 0) |
| Visit 3 (Day 22) 2 hrs post instillation | 0 (0 to 0) | 0 (0 to 0) |
| Visit 3 (Day 22) 4 hrs post instillation | 0 (0 to 0) | 0 (0 to 0) |
Blood samples will be collected to measure the concentration of ketotifen. Concentration values reported below the quantification limit (BLQ) before the first quantifiable concentration or after the last quantifiable concentration were set to zero for concentration descriptive statistics.
| ng/ml | Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution | Vehicle Ophthalmic Solution |
|---|---|---|
| Visit 1 (Day 1) Pre-instillation | 0 (0 to 0) | 0 (0 to 0) |
| Visit 1 (Day 1) 15 min post instillation | 0 (0 to 0) | 0 (0 to 0) |
| Visit 1 (Day 1) 30 min post instillation | 0 (0 to 0) | 0 (0 to 00) |
| Visit 1 (Day 1) 1 hr post instillation | 0 (0 to 0) | 0 (0 to 0) |
| Visit 1 (Day 1) 2 hrs post instillation | 0 (0 to 0) | 0 (0 to 0) |
| Visit 1 (Day 1) 4 hrs post instillation | 0 (0 to 0) | 0 (0 to 0) |
| Visit 3 (Day 22) Pre-instillation | 0 (0 to 0) | 0 (0 to 0) |
| Visit 3 (Day 22) 15 min post instillation | 0 (0 to 0) | 0 (0 to 0) |
| Visit 3 (Day 22) 30 min post instillation | 0 (0 to 0) | 0 (0 to 0) |
| Visit 3 (Day 22) 1 hr post instillation | 0 (0 to 0) | 0 (0 to 0) |
| Visit 3 (Day 22) 2 hrs post instillation | 0 (0 to 0) | 0 (0 to 0) |
| Visit 3 (Day 22) 4 hrs post instillation | 0 (0 to 0) | 0 (0 to 0) |
Collected over Assessed throughout the study approximately 6-10 weeks. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution | 0/340 (0%) | 0/340 (0%) | 32/340 (9.4%) |
| Vehicle Ophthalmic Solution | 0/170 (0%) | 1/170 (0.6%) | 9/170 (5.3%) |
| Event | Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution | Vehicle Ophthalmic Solution |
|---|---|---|
| Acute CholecystitisGeneral disorders | 0/340 | 1/170 |
| Event | Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution | Vehicle Ophthalmic Solution |
|---|---|---|
| Eye disordersEye disorders | 17/340 | 3/170 |
| General disorders and administration site conditionsEye disorders | 13/340 | 2/170 |
| Instillation site irritationEye disorders | 13/340 | 2/170 |
| Conjunctival HyperaemiaEye disorders | 5/340 | 2/170 |
2 Subjects randomized to the vehicle group were not treated and they were excluded from the baseline participant's number
| Age, Continuous(years) | Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution | Vehicle Ophthalmic Solution | Total |
|---|---|---|---|
| Mean | 38.3 ± 19.71 | 38.7 ± 19.99 | 38.5 ± 19.79 |
| Age, Customized(Participants) | Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution | Vehicle Ophthalmic Solution | Total |
|---|---|---|---|
| Less or equal to 18 years | 66 | 38 | 104 |
| Between 18 and 64 years | 236 | 111 | 347 |
| Greater or equal to 64 years | 38 | 21 | 59 |
| Sex: Female, Male(Participants) | Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution | Vehicle Ophthalmic Solution | Total |
|---|---|---|---|
| Female | 216 | 106 | 322 |
| Male | 124 | 64 | 188 |
| Ethnicity (NIH/OMB)(Participants) | Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution | Vehicle Ophthalmic Solution | Total |
|---|---|---|---|
| Hispanic or Latino | 21 | 12 | 33 |
| Not Hispanic or Latino | 319 | 158 | 477 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution | Vehicle Ophthalmic Solution | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 1 | 2 |
| Asian | 16 | 3 | 19 |
| Native Hawaiian or Other Pacific Islander | 3 | 2 | 5 |
| Black or African American | 63 | 28 | 91 |
| White | 253 | 127 | 380 |
| More than one race | 3 | 6 | 9 |
| Unknown or Not Reported | 1 | 3 | 4 |
| Region of Enrollment(participants) | Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution | Vehicle Ophthalmic Solution | Total |
|---|---|---|---|
| United States | 340 | 170 | 510 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2023 to primary completion in Sep 2023, 4 months.
Results were first posted in Jul 2025, 1 year 9 months after primary completion.
Of 21 phase 3 interventional studies under Conjunctivitis, Allergic, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 14. This study's 4 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brimonidine